Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

被引:150
作者
Proctor, NJ [1 ]
Tucker, GT [1 ]
Rostami-Hodjegan, A [1 ]
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Clin Sci Div S, Sheffield S10 2JF, S Yorkshire, England
关键词
D O I
10.1080/00498250310001646353
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Recombinantly expressed human cytochromes P450 (rhCYPs) have been underused for the prediction of human drug clearance (CL). 2. Differences in intrinsic activity (per unit CYP) between rhCYP and human liver enzymes complicate the issue and these discrepancies have not been investigated systematically. We define intersystem extrapolation factors (ISEFs) that allow the use of rhCYP data for the in vitro - in vivo extrapolation of human drug CL and the variance that is associated with interindividual variation of CYP abundance due to genetic and environmental effects. 3. A large database (n = 451) of metabolic stability data has been compiled and used to derive ISEFs for the most commonly used expression systems and CYP enzymes. 4. Statistical models were constructed for the ISEFs to determine major covariates in order to optimize experimental design to increase prediction accuracy. 5. Suggestions have been made for the conduct of future studies using rhCYP to predict human drug clearance.
引用
收藏
页码:151 / 178
页数:28
相关论文
共 133 条
[61]   CYTOCHROME-P450TB (CYP2C) - A MAJOR MONOOXYGENASE CATALYZING DICLOFENAC 4'-HYDROXYLATION IN HUMAN LIVER [J].
LEEMANN, T ;
TRANSON, C ;
DAYER, P .
LIFE SCIENCES, 1993, 52 (01) :29-34
[62]   Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling [J].
Lightfoot, T ;
Ellis, SW ;
Mahling, J ;
Ackland, MJ ;
Blaney, FE ;
Bijloo, GJ ;
De Groot, MJ ;
Vermeulen, NPE ;
Blackburn, GM ;
Lennard, MS ;
Tucker, GT .
XENOBIOTICA, 2000, 30 (03) :219-233
[63]   Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans [J].
Lucas, D ;
Ferrara, R ;
Gonzalez, E ;
Bodenez, P ;
Albores, A ;
Manno, M ;
Berthou, F .
PHARMACOGENETICS, 1999, 9 (03) :377-388
[64]  
Madan A, 2002, DRUG DRUG INTERACTIO, P217
[65]   Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines [J].
Madani, S ;
Paine, MF ;
Lewis, L ;
Thummel, KE ;
Shen, DD .
PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1199-1205
[66]  
Maenpaa J, 1998, PHARMACOGENETICS, V8, P137
[67]   Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: Particular efficiency and regioselectivity of P4502Cs [J].
Mancy, A ;
Antignac, M ;
Minoletti, C ;
Dijols, S ;
Mouries, V ;
Duong, NTH ;
Battioni, P ;
Dansette, PM ;
Mansuy, D .
BIOCHEMISTRY, 1999, 38 (43) :14264-14270
[68]   Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates [J].
Mankowski, DC ;
Lawton, MP ;
Ekins, S .
XENOBIOTICA, 2000, 30 (08) :745-754
[69]  
Masimirembwa CM, 1999, DRUG METAB DISPOS, V27, P1117
[70]   Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6 [J].
Mautz, DS ;
Shen, DD ;
Nelson, WL .
PHARMACEUTICAL RESEARCH, 1995, 12 (12) :2053-2056